You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)搭建心腦血管精準介入器械海外研發平台 合作開發全球創新血管內震波鈣化處理系統
格隆匯 08-02 18:03

格隆匯8月2日丨遠大醫藥(00512.HK)發佈公吿,集團與美國FastWave Medical Inc簽署一系列投資及戰略合作協議,其中,集團將分階段以最多共7200萬美元為代價取得FastWave100%的股權,另以投入最多800萬美元用作支持和合作進行開發用作治療中、重度動脈鈣化的創新醫療器械血管內震波鈣化處理系統。未來,在相關條件獲得滿足後,FastWave有望成為集團在心腦血管精準介入器械領域的全資附屬公司及海外高端創新醫療器械研發平台。

公吿表示,集團將要開發的血管內震波鈣化處理系統將治療腎結石的體外衝擊波碎石術應用於血管內,利用通用球囊擴張導管平台,集成震波碎石技術與球囊導管血管成形技術,通過介入方式將導管輸送至病灶血管腔內,破壞鈣化灶的同時不造成血管內壁/內膜軟組織損傷,降低球囊擴張及支架植入的併發症。產品使用難度低,學習曲線短,具有高度應用通用性,有望成為嶄新的鈣化病變治療方案。

目前中國國內治療血管內鈣化病變的產品依賴於進口,存在着巨大的未被滿足的臨牀需求。此次,集團對於血管內震波鈣化處理系統的開發有望為中國血管內鈣化病變患者帶來新的治療手段。同時,FastWave基於豐富的醫療器械開發經驗,將成為集團高端醫療器械海外研發平台,為創新產品的研發奠定基礎。

集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為源動力,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“全球化運營佈局,雙循環經營發展”策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account